Glucosio Baxter S.P.A.

Glucosio Baxter S.P.A. is an intravenous solution for injection that contains glucose monohydrate as the active ingredient. It is supplied in a sterile aqueous solution form, marketed in the European Union and available by prescription. The product provides a readily available source of glucose for patients requiring parenteral nutrition or rapid correction of low blood sugar levels and can be administered under controlled clinical conditions.

Glucosio Baxter is indicated for clinical situations where an immediate source of carbohydrate is required.

- Parenteral nutrition as part of total nutrient admixtures for patients unable to receive enteral feeding. - Treatment of acute hypoglycemia in emergency or perioperative settings. - Support during prolonged fasting or pre‑operative fasting when oral intake is not possible. - Dilution and compatible mixing with other intravenous medications for fluid replacement. - Management of glucose requirements in critically ill patients under intensive care monitoring.

Glucosio Baxter may be associated with infusion‑related reactions, although many patients tolerate the solution without notable events.

Common: - Local irritation at the injection site - Transient hyperglycemia - Mild electrolyte shifts (e.g., sodium, potassium) - Nausea or mild abdominal discomfort

Serious: - Severe hyperglycemia leading to osmotic diuresis - Allergic or anaphylactic reaction to the solution components - Fluid overload causing pulmonary edema - Metabolic acidosis in susceptible patients

When prescribing Glucosio Baxter, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Use caution in patients with diabetes mellitus, renal impairment, or heart failure. - Adjust infusion rate in neonates, infants, and pediatric patients due to different metabolic rates. - Monitor fluid balance and electrolytes, especially sodium and potassium, during prolonged administration. - Avoid rapid bolus administration unless clinically indicated. - Verify compatibility with other intravenous solutions to prevent precipitation. - Document any adverse reactions in the patient’s medical record.

Glucosio Baxter can interact with other agents administered intravenously or affect systemic metabolic pathways.

Avoid: - Concurrent high‑dose insulin infusions without glucose monitoring, which may precipitate severe hypoglycemia. - Co‑administration with other hypertonic glucose solutions, increasing risk of hyperosmolar complications. - Use with potassium‑rich solutions without electrolyte monitoring, risking hyperkalemia.

Use with caution: - Simultaneous administration of diuretics that may alter fluid and electrolyte status. - Concurrent use of corticosteroids, which can raise blood glucose levels. - Combination with beta‑adrenergic agonists that may affect glucose metabolism.